The News
Proviral DNA & Viremia Rebound PDF Print E-mail
Written by Alain Lafeuillade   
Saturday, 30 October 2010 16:12

Rebound of Plama Viremia Following Cessation of Antiretroviral Therapy Despite Profoundly Low Levels of HIV Reservoir: implication for eradication

Chun TW, Justement JS, Murray D et al. AIDS 2010; 24: Oct. 19, Pub ahead of print.

he authors have analysed the 'residual' HIV-1 reservoir in 44 patients with long term ART-induced suppression of plasma viremia. They have measured both levels of proviral DNA in highly purified CD4+ T cells and infectious virus by high-input quantitative co-culture assays. Furthermore, HIV-1 DNA was also measured in gut biopsies taken from 2 patients. In one patient with extraordinarily low levels of the reservoir, ART was discontinued...
Last Updated on Friday, 19 November 2010 17:16
Towards a Cure for HIV PDF Print E-mail
Written by Alain Lafeuillade   
Friday, 29 October 2010 15:13

Towards a Cure for HIV: the identification and characterization of HIV reservoirs in optimally treated people.

Onafuwa-Nuga A, McNamara LA, Collins KL. Cell Research 2010; Sept. 28, Pub ahead of print.

tudies of viral load decay during HAART have suggested the existence of other reservoirs than latently infected CD4+ T cells. Several experiments have demonstrated that multipotent hematopoietic stem/precursor cells (HSPCs) can become infected with HIV-1.
Last Updated on Friday, 19 November 2010 17:19
HIV Production and p21 Expression PDF Print E-mail
Written by Vincent Kapoulos   
Thursday, 28 October 2010 07:50

Researchers at the 48th IDSA Meeting Find a Correlation Between p21 Expression and HIV Production in CD4+ T Cells

 Vancouver, Canada, 48th Annual Meeting of the Infectious Diseases Society of America, 22 OCT. 2010

athias Lichterfeld, MD, PhD, from the Infectious Diseases Division at Massachusetts General Hospital, showed his research study focusing on HIV replication in CD4 T cells from elite controllers (n = 15), from HIV-1 negative individuals (n = 14), from individuals with progressive HIV-1 disease (n = 16), and from infected patients treated with highly active antiretroviral therapy (HAART) (n = 10).


Last Updated on Friday, 19 November 2010 17:22
Effect of Raltegravir Intensification in Gut PDF Print E-mail
Written by Alain Lafeuillade   
Sunday, 24 October 2010 08:05

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Yukl SA, Shergill AK, McQuaid K, Gianella S et al. AIDS 210, Oct 23; 24 (16): 2451-60.

ased on the assumption that plasma might not reflect changes elsewhere in the body, especially in the lymphoid tissues, the authors analyzed the effects of 12 weeks of ART intensification with raltegravir (RLG) alone or in combination with efavirenz (EFV) or darunavir (DRV) in 7 patients at different levels in the gut.

Last Updated on Friday, 19 November 2010 17:29
Presentation HIV Reservoirs Tropea PDF Print E-mail
Written by Alain Lafeuillade   
Friday, 15 October 2010 16:52

Dr Lafeuillade, IHV Meeting Presentation, Tropea,  October 9, 2010:

"HIV Persistence Challenging Therapeutic Success"

Lecture given at the 12th Annual Meeting of the Institute of Human Virology.


Listen to the Presentation

Last Updated on Friday, 29 October 2010 15:43
<< Start < Prev 31 32 33 34 35 36 37 38 39 Next > End >>

Page 39 of 39